Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exenatide as Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes~* Treating diabetes with diet and exercise~* HbA1c between 6.5% and 10.0%, inclusive~* Body Mass Index (BMI) between 25 kg/m\^2 and 45 kg/m\^2, inclusive~Exclusion Criteria:~* Have previously completed or withdrawn from this study~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry~* Have been treated with any antidiabetic agent~* Have used drugs for weight loss (for example, Xenical, Meridia, Acutrim, or similar over-the counter medications) within 3 months of screening~* Are currently treated with any of the following excluded medications: \* drugs that directly affect gastrointestinal motility; \* systemic corticosteroids (excluding topical and inhaled preparations) by oral, intravenous, or intramuscular route used regularly (longer than 2 weeks) or used within 2 weeks immediately prior to screening for this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide 5 mcg/exenatide 5 mcg (Type: EXPERIMENTAL): Exenatide 5 mcg; then exenatide 5 mcg
- Exenatide 5 mcg/exenatide 10 mcg (Type: EXPERIMENTAL): Exenatide 5 mcg, then exenatide 10 mcg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in volumes equivalent to exenatide

Based on this trial design, predict the completion outcome and termination type (if applicable).